The disclosure relates to four new cocrystalline forms of dehydroepiandrosterone (DHEA). The disclosed cocrystalline forms are: DHEA-D-fructose cocrystal, DHEA-eglutaric acid cocrystal, DHEA-maleic acid cocrystal and DHEA-L-tartaric acid cocrystal. The disclosure also relates to processes for how to prepare these cocrystals in greater quantities. The disclosure is made with the intention to obtain patent protection on these compounds and to improve the physiochemical properties of DHEA, whereby one or several of these compounds may be suitable for drug development. DHEA is in vivo metabolized to ADIOL (5-androstene-3[3,17[3-diol), an estrogen receptor beta (ERβ) agonist with unique properties of inhibiting neuroinflammation in animal models (see e.g. Saijo et aI., Cell 145, 584-595, 2011). Accordingly, the novel crystalline forms of DHEA may find utility in the context of treating different diseases in which ERβ has been implicated in the pathophysiology including neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS).